[go: up one dir, main page]

CA2784861A1 - Butyrylcholinesterases recombinantes et produits de troncature de ceux-ci - Google Patents

Butyrylcholinesterases recombinantes et produits de troncature de ceux-ci Download PDF

Info

Publication number
CA2784861A1
CA2784861A1 CA2784861A CA2784861A CA2784861A1 CA 2784861 A1 CA2784861 A1 CA 2784861A1 CA 2784861 A CA2784861 A CA 2784861A CA 2784861 A CA2784861 A CA 2784861A CA 2784861 A1 CA2784861 A1 CA 2784861A1
Authority
CA
Canada
Prior art keywords
nucleic acid
isolated nucleic
polypeptide
bche
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2784861A
Other languages
English (en)
Inventor
Kalvin Yim
Steven Danso
Edward Hausknecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altimmune Inc
Original Assignee
Pharmathene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmathene Inc filed Critical Pharmathene Inc
Publication of CA2784861A1 publication Critical patent/CA2784861A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2784861A 2009-12-21 2010-12-21 Butyrylcholinesterases recombinantes et produits de troncature de ceux-ci Abandoned CA2784861A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28444409P 2009-12-21 2009-12-21
US61/284,444 2009-12-21
PCT/US2010/003225 WO2011084145A2 (fr) 2009-12-21 2010-12-21 Butyrylcholinestérases recombinantes et produits de troncature de ceux-ci

Publications (1)

Publication Number Publication Date
CA2784861A1 true CA2784861A1 (fr) 2011-07-14

Family

ID=44306009

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2784861A Abandoned CA2784861A1 (fr) 2009-12-21 2010-12-21 Butyrylcholinesterases recombinantes et produits de troncature de ceux-ci

Country Status (6)

Country Link
US (2) US8729245B2 (fr)
EP (1) EP2516664B1 (fr)
JP (1) JP2013526840A (fr)
AU (1) AU2010340358B2 (fr)
CA (1) CA2784861A1 (fr)
WO (1) WO2011084145A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8729245B2 (en) 2009-12-21 2014-05-20 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
US9688970B2 (en) 2013-10-01 2017-06-27 Kentucky Bioprocessing, Inc. Plant-based recombinant butyrylcholinesterase production methods
MD3286209T2 (ro) * 2015-04-24 2021-04-30 Ferring Bv Metodă de producere a gonadotrofinei
BR112018007453A2 (pt) * 2015-11-05 2018-10-23 Bamboo Therapeutics Inc genes modificados de ataxia de friedreich e vetores para a terapia gênica
CN108486114A (zh) * 2018-04-18 2018-09-04 西南大学 实现两个基因等量表达的基因元件及表达载体
EP3964265A1 (fr) * 2020-09-07 2022-03-09 Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz Cellules souches mésenchymateuses co-exprimant cxcr4 et il-10 et leurs utilisations

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US6727405B1 (en) 1986-04-09 2004-04-27 Genzyme Corporation Transgenic animals secreting desired proteins into milk
US5215909A (en) 1986-06-18 1993-06-01 Yeda Research & Development Co., Ltd. Human cholinesterase genes
US5322775A (en) 1986-06-30 1994-06-21 Pharmaceutical Proteins Ltd. Peptide production
EP0832981A1 (fr) 1987-02-17 1998-04-01 Pharming B.V. Séquences d'ADN pour diriger des protéines vers les glandes mammaires, afin d'être secrétées efficacement
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
IL89703A (en) 1989-03-21 2001-10-31 Yissum Res Dev Co Polynucleotide encoding human acetylcholinesterase, vectors comprising said polynucleotide, cells transformed by said vectors, enzyme produced by said transformed cell, and uses thereof
US5227301A (en) 1989-11-03 1993-07-13 The 501 Institution For The Advancement Of Learning (Mcgill University) Immortalized bovine mannary epithelial cell line
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5831141A (en) 1991-01-11 1998-11-03 United States Of America As Represented By The Department Of Health And Human Services Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter
US6110742A (en) 1992-04-15 2000-08-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Synthetic antisense oligodeoxynucleotides targeted to AChE
IL101600A (en) 1992-04-15 2000-02-29 Yissum Res Dev Co Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them
ATE193301T1 (de) 1993-03-09 2000-06-15 Genzyme Corp Verfahren zur isolierung von proteinen aus milch
US5610053A (en) 1993-04-07 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells
DE4326665C2 (de) 1993-08-09 1995-07-13 Biotest Pharma Gmbh Verfahren zur Sterilfiltration von Milch
US5932780A (en) 1994-02-28 1999-08-03 Yissum Research Development Company Of Hebrew University Of Jerusalem Transgenic non-human animal assay system for anti-cholinesterase substances
US6025183A (en) 1994-02-28 2000-02-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Transgenic animal assay system for anti-cholinesterase substances
US6204431B1 (en) 1994-03-09 2001-03-20 Abbott Laboratories Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk
US5807671A (en) 1995-01-09 1998-09-15 Yissum Research Development Company Of Hebrew University Of Jerusalem Method of screening for genetic predisposition to anticholinesterase therapy
US5780009A (en) 1995-01-20 1998-07-14 Nexia Biotechnologies, Inc. Direct gene transfer into the ruminant mammary gland
US6001625A (en) 1995-05-19 1999-12-14 The United States Of America As Represented By The Secretary Of The Army Site-directed mutagenesis of esterases
IL115873A0 (en) 1995-11-03 1996-01-31 Peri Dev Applic 1985 Ltd Transgenic protein production
US6326139B1 (en) 1996-01-11 2001-12-04 Yissum Research Development Company Of Hebrew University Of Jerusalem Method of screening for genetic predisposition to anticholinesterase therapy
US6268487B1 (en) 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
US20020184655A1 (en) 1997-12-01 2002-12-05 Henryk Lubon Methods for the degradation and detoxification of organic material using urine produced by transgenic animals and related transgenic animals and proteins
US7157615B2 (en) 1998-03-17 2007-01-02 Nexia Biotechnologies, Inc. Production of biofilaments in transgenic animals
AU755334C (en) 1998-08-25 2004-02-26 University Of Washington Rapid quantitative analysis of proteins or protein function in complex mixtures
CA2343104A1 (fr) 1998-09-16 2000-03-23 Nexia Biotechnologies, Inc. Production de proteines recombinantes dans l'urine
US6580017B1 (en) 1998-11-02 2003-06-17 Genzyme Transgenics Corporation Methods of reconstructed goat embryo transfer
AU1621900A (en) 1998-11-13 2000-06-05 New York University Transgenic animals as urinary bioreactors for the production of protein in the urine, recombinant dna construct for kidney-specific expression, and method of using same
CA2354638C (fr) 1999-01-06 2013-03-19 Atlantic Biopharmaceuticals, Inc. Expression d'alpha-foetoproteines humaines secretees chez des animaux transgeniques
US7297680B2 (en) * 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
EP1175453B1 (fr) 1999-04-26 2003-10-29 U.S. Army Medical Research and Materiel Command Eponges de detoxication a reactions multiples pour composes organo-phosphores
IL131707A0 (en) 1999-05-31 2001-03-19 Yissum Res Dev Co Acetylcholinesterase-derived peptides and uses thereof
WO2001071014A2 (fr) 2000-03-17 2001-09-27 Boyce Thompson Institute For Plant Research, Inc. Expression d'acetylcholinesterase de recombinaison humaine dans des plantes transgeniques
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001261024A1 (en) 2000-04-12 2001-10-30 Delta Biotechnology Limited Albumin fusion proteins
US7070973B2 (en) 2000-12-26 2006-07-04 Board Of Regents Of The University Of Nebraska Butyrylcholinesterase variants and methods of use
IL142875A (en) 2001-04-30 2009-08-03 Avigdor Shafferman PEG-linked cholinesterases for the detoxification of circulating organophosphorus
AR033903A1 (es) 2001-05-21 2004-01-07 Inhale Therapeutic Syst Una composicion de insulina modificada quimicamente para la administracion pulmonar
CN101988071B (zh) * 2001-10-11 2016-07-06 默沙东公司 丙型肝炎病毒疫苗
US7078507B2 (en) 2001-11-09 2006-07-18 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Synthetic genes for malarial proteins and methods of use
AU2002353374A1 (en) 2001-12-21 2003-07-09 Nexia Biotechnologies, Inc. Production of butyrylcholinesterases in transgenic mammals
US20080213281A1 (en) * 2002-12-04 2008-09-04 Applied Molecular Evolution, Inc. C/O Eli Lilly And Company Patent Division Butyrylcholinesterase Variants that Alter the Activity of Chemotherapeutic Agents
WO2005035788A2 (fr) 2003-10-10 2005-04-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Procede et kit d'evaluation de l'anxiete ou de disposition a l'anxiete chez un sujet
DE602004020855D1 (de) 2003-11-20 2009-06-10 Hoffmann La Roche Spezifische Marker für Stoffwechselssyndrome
EP1756272A2 (fr) 2004-01-09 2007-02-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Composes, compositions pharmaceutiques et procedes therapeutiques pour prevenir et traiter des maladies et des troubles associes a la formation de fibrilles amyloides
US20060194301A1 (en) 2004-10-09 2006-08-31 Doctor Bhupendra P Large-scale production of human serum butyrylcholinesterase as a bioscavenger
US9062321B2 (en) 2004-12-01 2015-06-23 Arizona Board Of Regents On Behalf Of Arizona State University Codon-optimized polynucleotides encoding human butyrylcholinesterase and plant expression systems therof
US20090249503A1 (en) 2004-12-06 2009-10-01 Bolder Biotechnology, Inc. Enzyme conjugates for use as detoxifying agents
IL169377A (en) 2005-06-23 2012-09-24 Avigdor Shafferman Uniformly conjugated serine hydrolases
JP5250850B2 (ja) * 2006-06-29 2013-07-31 ディーエスエム アイピー アセッツ ビー．ブイ． 改善されたポリペプチド発現を達成する方法
EP2049661A4 (fr) 2006-08-04 2012-07-04 Pharmathene Inc Butyrylcholinestérase recombinante à demi-vie longue
EA022990B1 (ru) * 2007-08-20 2016-04-29 Глаксо Груп Лимитед Способ получения клеточной линии млекопитающего, продуцирующей терапевтический белок
US7846428B2 (en) * 2007-10-05 2010-12-07 Merial Limited Articular cartilage gene therapy with recombinant vector encoding BMP-7
US8729245B2 (en) 2009-12-21 2014-05-20 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof

Also Published As

Publication number Publication date
WO2011084145A2 (fr) 2011-07-14
US8729245B2 (en) 2014-05-20
EP2516664B1 (fr) 2015-07-22
AU2010340358A1 (en) 2012-07-19
EP2516664A4 (fr) 2013-11-13
US20120252094A1 (en) 2012-10-04
AU2010340358B2 (en) 2014-07-24
EP2516664A1 (fr) 2012-10-31
US8952143B2 (en) 2015-02-10
JP2013526840A (ja) 2013-06-27
US20140220658A1 (en) 2014-08-07
WO2011084145A3 (fr) 2013-05-30

Similar Documents

Publication Publication Date Title
US8952143B2 (en) Recombinant butyrylcholinesterases and truncates thereof
McBlane et al. Cleavage at a V (D) J recombination signal requires only RAG1 and RAG2 proteins and occurs in two steps
EP2539445B1 (fr) Utilisation d'endonucléases pour insérer des transgènes dans des locus safe harbor
KR20210125560A (ko) 유전성 질환의 치료를 위한 것을 포함하는, 아데노신 데아미나제 염기 편집기를 사용한 질환-관련 유전자의 스플라이스 수용체 부위 파괴
EP4428232A1 (fr) Protéine de cas13 isolée et son utilisation
JP2022097653A (ja) ヒトα－ガラクトシダーゼバリアント
KR20160050069A (ko) Cas9 변이체 및 그의 용도
EP2910632B1 (fr) Enzyme hautement fonctionnelle ayant une spécificité de substrat béta-hexosaminidase b humaine modifiée, et présentant une résistance à la protéase
KR20170120126A (ko) 숙주 세포 단백질 변형
US20090217400A1 (en) Enzymes, cells and methods for site specific recombination at asymmetric sites
US20240307558A1 (en) Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of KRT5, KRT14, LAMB3, and COL7A1 genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-KRT5, or Escherichia coli strain SCS110-AF/VTvaf17-KRT14, or Escherichia coli strain SCS110-AF/VTvaf17-LAMB3, or Escherichia coli strain SCS110-AF/VTvaf17-COL7A1 carrying the gene therapy DNA vector, m
EP4347816A1 (fr) Systèmes crispr de classe ii, de type v
Ceylan et al. Cloning, expression, and characterization of human brain acetylcholinesterase in Escherichia coli using a SUMO fusion tag
US5248604A (en) Enzymatically active recombinant human acetylcholinesterase and hosts and vectors for expression thereof
US8318155B2 (en) Nucleic acid cleaving agent
EP3473709B1 (fr) Vecteur adn contenant un gène codant pour une butyrylcholinestérase équine, pour transformation et intégration dans le chromosome de leishmania tarentolae.
WO1993001830A1 (fr) Expression de l'acetylcholinesterase humaine de recombinaison active sur le plan enzymatique et ses utilisations
US20090311743A1 (en) Process for the Production, in Prokaryotes, of Active, Stable Transposases of Mariner Mobile Genetic Elements
RU2732795C1 (ru) Рекомбинантный слитый белок
JP2641273B2 (ja) 変異型ヒトリゾチーム
CN120665840A (zh) Cas9蛋白突变体及其应用
CA3194019A1 (fr) Complexe contenant une cytidine desaminase miniaturise pour modifier l'adn double brin
Fischer et al. Production of Enzymatically Active Human Acetylcholinesterase in E. Coli

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20161221